Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

231
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
231
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

322
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
322
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

459
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
459
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

594
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
594
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

1.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.4K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

801
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
801

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
Same author

Prognostic Utility of the BCIS-CHIP Score in Imaging-Guided Percutaneous Coronary Intervention.

The American journal of cardiology·2026
Same author

Baseline Prolonged QRS Duration May Predict In-Hospital Outcomes of Patients With Acute Myocarditis: Multicenter Observational Study.

Circulation reports·2026
Same author

Current status of eradication therapy and antimicrobial susceptibility testing for Helicobacter pylori in Japan: A nationwide questionnaire survey.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Minimizing command timing variability is a key factor in skilled actions.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Prognostic impact of pre-procedural blood pressure profiles on clinical outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Heart and vessels·2025

Related Experiment Video

Updated: Nov 16, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

680

Evidence-based clinical practice guidelines for peptic ulcer disease 2020.

Tomoari Kamada1,2, Kiichi Satoh3, Toshiyuki Itoh3

  • 1Department of Health Care Medicine, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-ku, Okayama, 700-8505, Japan. tkamada@med.kawasaki-m.ac.jp.

Journal of Gastroenterology
|February 23, 2021
PubMed
Summary
This summary is machine-generated.

The 2020 Japanese clinical practice guidelines for peptic ulcer disease offer updated evidence-based recommendations. They cover H. pylori eradication, NSAID-induced ulcers, and prevention strategies, including vonoprazan and PPIs.

Keywords:
Helicobacter pylori eradicationIdiopathic ulcerLow-dose aspirinNonsteroidal anti-inflammatory drugPeptic ulcer

More Related Videos

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

3.8K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.8K

Related Experiment Videos

Last Updated: Nov 16, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

680
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

3.8K
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.8K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pharmacology

Background:

  • The Japanese Society of Gastroenterology (JSGE) updated its evidence-based clinical practice guidelines for peptic ulcer disease in 2020.
  • An English version of these comprehensive guidelines is now available.

Purpose of the Study:

  • To provide updated, evidence-based clinical practice guidelines for the management of peptic ulcer disease.
  • To outline therapeutic algorithms for various peptic ulcer types and complications.
  • To detail strategies for the prevention of NSAID- and aspirin-related ulcers.

Main Methods:

  • The guidelines cover nine key areas: epidemiology, hemorrhagic ulcers, H. pylori eradication, non-eradication therapy, drug-induced ulcers, remnant ulcers, surgical treatment, and conservative management of perforation/stenosis.
  • Therapeutic algorithms are presented based on ulcer complications and patient history.
  • Recommendations for H. pylori eradication include vonoprazan (VPZ) with antibiotics as first-line and PPIs or VPZ as second-line therapy.

Main Results:

  • Treatment algorithms differ based on ulcer complications, such as NSAID-induced ulcers.
  • For H. pylori eradication, VPZ with antibiotics is recommended first-line.
  • Prevention algorithms for NSAID- and LDA-related ulcers are provided, varying by concomitant medication use and ulcer history.

Conclusions:

  • The guidelines offer structured approaches to peptic ulcer management, emphasizing H. pylori eradication and prevention of NSAID/aspirin-induced ulcers.
  • Vonoprazan and proton pump inhibitors (PPIs) are key pharmacotherapies recommended.
  • Specific algorithms guide the prevention of ulcer recurrence in patients on NSAIDs or low-dose aspirin.